Drug intelligence / Profile preview

XL-510

Development stage
Preclinical
Lead developer
XL-protein
Modality
Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Subcutaneous
01

Overview

XL-510 is a PAS polymer developed by XL-protein as a biodegradable alternative to polyethylene glycol (PEG) for the modification of biopharmaceuticals, a technology known as PASylation. The substance consists of genetically encoded, conformationally disordered sequences of the amino acids Proline, Alanine, and Serine (PAS). When fused or conjugated to therapeutic proteins or peptides, XL-510 increases the hydrodynamic volume of the molecule, which significantly reduces renal clearance and extends the plasma half-life. Unlike synthetic PEG, PAS polymers are biodegradable and generally non-immunogenic, potentially avoiding the formation of anti-drug antibodies that can compromise treatment efficacy. XL-510 serves as a foundational component for various drug candidates in XL-protein's pipeline, aimed at improving the pharmacokinetic profiles of cytokines, enzymes, and antibody fragments.

Other names
PAS substancePEG substitute (PAS)PAS polymer

Beyond the preview

Go deeper on XL-510.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on XL-510.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call